Abstract 183P
Background
In Asia, the standard treatment for locally advanced gastric cancer (LAGC) involves gastrectomy with D2 dissection and adjuvant chemotherapy. However, achieving adequate chemotherapy intensity after gastrectomy presents challenges. Previous trials have shown the effectiveness of neoadjuvant chemotherapy (NAC). Nevertheless, limited research has been conducted to explore the feasibility of NAC-SOX for older patients with LAGC. This phase II study (KSCC1801) aimed to assess the safety and efficacy of NAC-SOX in LAGC patients aged ≥ 70 years. Herein, we present the conclusive data analysis of KSCC1801, shedding light on its outcomes.
Methods
Patients received NAC consisting of three cycles of SOX130 (oxaliplatin 130 mg/m2 on day 1, oral S-1 40-60 mg twice daily for two weeks every three weeks), followed by gastrectomy with lymph node dissection. The primary endpoint was the dose intensity (DI) of the treatment. Secondary endpoints included safety, R0 resection rate, pathological response rate (pRR), overall survival, and relapse-free survival.
Results
The study enrolled 26 patients with a median age of 74.5 years. The median DI in the NAC-SOX130 treatment was 97.2% for S-1 and 98.3% for oxaliplatin. NAC was successfully administered to 25 patients (96.2%), among whom 24 (92.3%) underwent gastrectomy with lymphadenectomy. The R0 resection rate was 92.3%, and the pRR (≥ grade 1b) was 62.5%. Major adverse events (≥ grade 3) included neutropenia (20.0%), thrombocytopenia (11.5%), anorexia (11.5%), nausea (7.7%), and hyponatremia (7.7%). Postoperative complications such as abdominal infection, elevated blood amylase, and bacteremia occurred in one patient each. The 1- and 2-year OS rates were 93.3% and 89.7%, respectively. The 1- and 2-year RFS rates were 68.7% and 58.6%, respectively.
Conclusions
NAC-SOX130 proves to be a feasible therapy for older patients aged ≥ 70 years.
Clinical trial identification
jRCTs071180001.
Editorial acknowledgement
Legal entity responsible for the study
KSCC (Kyushu Study group of Clinical Cancer).
Funding
Yakult Honsha.
Disclosure
E. Oki: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Bayer, Eli Lilly, Bristol-myers Squibbb, MSD; Financial Interests, Personal and Institutional, Research Grant: Guardant Health. All other authors have declared no conflicts of interest.
Resources from the same session
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract